{"version":"1.0","type":"link","title":"Cost-effectiveness of pembrolizumab for the first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma in Colombia.","author_name":"Urrego-Reyes J 외","author_url":"https://prs-insight.online/author/Urrego-Reyes%20J","provider_name":"PRSinsight","provider_url":"https://prs-insight.online","thumbnail_url":"https://prs-insight.online/og/paper/170203","thumbnail_width":1200,"thumbnail_height":630}